Steven L Barriere
Overview
Explore the profile of Steven L Barriere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niederman M, Lee P, Barriere S, Barnes C, Castaneda-Ruiz B
Infect Dis Ther
. 2019 Aug;
8(3):445-452.
PMID: 31372837
Introduction: The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with vancomycin minimum inhibitory concentration (MIC) ≥ ...
2.
Smart J, Corey G, Stryjewski M, Wang W, Barriere S
Diagn Microbiol Infect Dis
. 2017 Jan;
87(3):268-271.
PMID: 28038840
The broth microdilution (BMD) MIC testing method for telavancin was recently revised BMD (rBMD) to improve accuracy and reproducibility. Staphylococcus aureus isolates from telavancin phase 3 complicated skin and skin-structure...
3.
Smart J, Corey G, Stryjewski M, Wang W, Barriere S
Infect Dis Ther
. 2016 Oct;
5(4):535-544.
PMID: 27718118
Introduction: The broth microdilution method (BMD) for testing telavancin minimum inhibitory concentrations (MICs) was revised (rBMD) in 2014 to improve the accuracy, precision, and reproducibility of the testing method. The...
4.
Lacy M, Stryjewski M, Wang W, Hardin T, Nogid B, Luke D, et al.
Clin Infect Dis
. 2015 Aug;
61 Suppl 2:S87-93.
PMID: 26316562
Background: When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram-negative pathogens or both (mixed infections), the adequacy of gram-negative coverage (GNC) can confound the assessment of...
5.
Pushkin R, Barriere S, Wang W, Corey G, Stryjewski M
Antimicrob Agents Chemother
. 2015 Aug;
59(10):6170-4.
PMID: 26248356
Two phase 3 ATLAS trials demonstrated noninferiority of telavancin compared with vancomycin for complicated skin and skin structure infections. Data from these trials were retrospectively evaluated according to 2013 U.S....
6.
Worboys P, Wong S, Barriere S
Eur J Clin Pharmacol
. 2015 May;
71(6):707-714.
PMID: 25939708
Purpose: We evaluated the effect of renal impairment (RI) on the pharmacokinetics of telavancin and hydroxypropylbetadex (excipient in the telavancin drug product). Methods: Adults with normal, mild, moderate or severe...
7.
Barriere S
Expert Opin Pharmacother
. 2014 Dec;
16(2):151-3.
PMID: 25483564
The concern over antibiotic resistance has been voiced since the discovery of modern antibiotics > 75 years ago. The concerns have only increased with time, with efforts to control resistance...
8.
Corey G, Rubinstein E, Stryjewski M, Bassetti M, Barriere S
Clin Infect Dis
. 2014 Dec;
60(5):787-96.
PMID: 25472944
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA). Treatment is challenging, particularly for...
9.
Barriere S, Farrell D, Rhomberg P, Jones R
Diagn Microbiol Infect Dis
. 2014 Oct;
80(4):327-9.
PMID: 25306423
Telavancin biological activity, determined by serum titers against a reference strain of Staphylococcus aureus, was maintained in the serum of subjects with severe renal impairment or end-stage renal disease suggesting...
10.
McConeghy K, Liao S, Clark D, Worboys P, Barriere S, Rodvold K
Antimicrob Agents Chemother
. 2014 Sep;
58(12):7093-7.
PMID: 25223996
Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against Gram-positive pathogens. Two brief reports have suggested potential cross-reactivity of telavancin with the vancomycin particle-enhanced turbidometric immunoassay (PETIA)....